View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 18, 2014

Merck’s NOXAFIL injection secures US FDA approval

The US Food and Drug Administration has approved Merck's antifungal agent NOXAFIL (posaconazole) injection (18mg/ mL), a new formulation for intravenous (IV) use.

The US Food and Drug Administration has approved Merck’s antifungal agent NOXAFIL (posaconazole) injection (18mg/ mL), a new formulation for intravenous (IV) use.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

The antifungal agent is also marketed as NOXAFIL (100mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension.

NOXAFIL injection, delayed-release tablets and oral suspension are indicated for prophylaxis of invasive Aspergillus and Candida infections.

It is indicated for patients who are at high-risk of developing these infections due to being severely immunocompromised such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

"The availability of a NOXAFIL formulation for intravenous administration is particularly important for those patients who may benefit from or require intravenous therapy."

NOXAFIL injection is indicated in patients 18 years and older, while the delayed-release tablets and oral suspension are indicated in patients 13 years and above.

The approval helps Merck provide an IV formulation and two oral formulations of NOXAFIL for prophylaxis against invasive Aspergillus and Candida infections in high-risk patients.

According to the company, NOXAFIL should not be given to people allergic to posaconazole or other azole antifungal medicines and should not be administered with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids.

Merck Research Laboratories executive director of infectious disease Nicholas Kartsonis said: "The availability of a NOXAFIL formulation for intravenous administration is particularly important for those patients who may benefit from or require intravenous therapy, or who, for a variety of reasons, might not be able to take an oral formulation.

"In addition, patients have the possibility to start on NOXAFIL injection and transition to oral NOXAFIL."

NOXAFIL injection is given with a loading dose of 300mg (one 300mg vial) twice a day on the first day of NOXAFIL therapy, then 300mg (one 300mg vial) once a day afterwards.

Once combined with a mixture of intravenous solution, NOXAFIL injection should be immediately administered through an in-line filter.

According to clinical trials, adverse reactions reported for NOXAFIL IV injection were generally similar in type to that reported in trials of NOXAFIL oral suspension.

Most frequently reported adverse reactions with an onset during the posaconazole intravenous phase of dosing 300mg once-daily therapy were diarrhea, hypokalemia, fever and nausea.

The company intends to make NOXAFIL injection available at wholesalers in mid-April.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology